Guggenheim reiterated a Buy rating and $40.00 price target on Horizon Pharma (NASDAQ: HZNP) following the company's 3Q15 earnings report ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34November 10, 2015 6:57 AM Pre-Open Stock Movers 11/06: (ZSPH) (LXRX) (WTW) Higher; (ICON) (MW) (KBIO) Lower (more...)November 6, 2015 9:28 AM Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue OutlookNovember 6, 2015 7:01 AM Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA GuidanceNovember 6, 2015 7:00 AM UPDATE: Trading Radar for 11/6: ArcelorMittal (MT), Cigna (CI), Scripps (SSP), Titan Int'l (TWI) ReportNovember 5, 2015 3:28 PM Horizon Pharma plc Announces Clinical Data to Be Presented at the 2015 ACR/ARHP Annual MeetingNovember 5, 2015 7:01 AM Deerfield's Flynn Staying Away from Valeant (VRX), Likes Horizon (HZNP) - Bloomberg November 4, 2015 3:34 PM Horizon Pharma (HZNP) patents on Ravicti to be review on Par challenge - BloombergNovember 4, 2015 10:30 AM Horizon Pharma plc to Present at Three Conferences in NovemberNovember 4, 2015 7:02 AM